Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement
- None.
- None.
Insights
The cooperative agreement between Smith+Nephew and the USAISR under the Master CRADA framework is a significant development in the field of medical technology, particularly for companies involved in Advanced Wound Management, Orthopaedics and Sports Medicine. This partnership may lead to accelerated innovation and development of new technologies and treatments that are crucial for improving combat casualty care.
From a research perspective, the collaboration grants Smith+Nephew access to the USAISR's extensive military medical expertise and patient population, which could result in the development of products tailored to the unique needs of military personnel. This could potentially open up a new market segment for Smith+Nephew, enhancing its product portfolio and potentially increasing market share in the medical technology sector.
The ability to conduct joint research also implies a sharing of costs and resources, which could result in more efficient use of R&D budgets and a quicker path to market for new innovations. This efficiency could be reflected in the company's financial performance, with potential cost savings and revenue generation from new products.
This Master CRADA between Smith+Nephew and the USAISR could position the company as a preferred partner for the Department of Defense in future procurement processes, potentially leading to significant contracts. Investors and stakeholders should be aware of the long-term benefits such as exclusive access to military contracts and a strengthened brand reputation within the medical technology industry.
Moreover, the collaboration could set a precedent for other companies in the industry, possibly sparking a trend towards similar agreements with military or government entities. It is important to monitor how competitors respond to this development and whether Smith+Nephew can leverage this agreement to gain a competitive advantage.
It is also crucial to consider how this partnership might influence the company's stock performance. A successful collaboration with tangible product outcomes could positively impact investor sentiment and Smith+Nephew's stock valuation, especially if the research leads to breakthroughs in medical technology.
The Master CRADA provides a broad legal framework that could significantly reduce bureaucratic barriers to initiating new research projects. The pre-negotiated terms and conditions streamline the process of establishing collaborative research, which can be a time-consuming and complex legal endeavor.
This legal framework is particularly relevant for Smith+Nephew as it allows for a more agile response to research opportunities and potentially a faster time-to-market for innovations. For stakeholders, this translates to a company that is better equipped to navigate the legal intricacies of government contracts, a non-trivial advantage in the heavily regulated medical technology industry.
It is also indicative of the trust and credibility that Smith+Nephew has established with the USAISR, suggesting that the company's compliance and regulatory affairs are well-managed. This could have positive implications for investor confidence, as it demonstrates the company's ability to secure and manage high-level government agreements.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company.
The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound Management, Orthopaedics and Sports Medicine - to enter into multiple collaborative research efforts.
“Smith+Nephew has a rich history supporting the military and partnering with the USAISR on this agreement furthers our purpose of helping people live their Life Unlimited,” said Rohit Kashyap, President, Advanced Wound Management and Commercial Operations at Smith+Nephew. “This agreement is exciting on many levels - not just for Smith+Nephew, but for our customers and their patients as well.”
The agreement enables efficient collaboration and strengthens the relationship between the USAISR and Smith+Nephew for future research endeavours in diverse areas of mutual interest. These types of cooperative efforts benefit both the Department of Defense (DOD) and industry leaders by providing opportunities to conduct joint research and learn from each other.
“The pre-negotiated key terms and conditions of the Master CRADA provide the broad legal framework under which for multiple, future collaborative research efforts will be assigned. In addition to streamlining the research agreement process, this Master CRADA provides the foundation for a strategic, joint effort to leverage the infrastructure, expertise, and capabilities of both parties to support innovation that aims to address technical challenges to improving combat casualty care,” said COL (Dr.) J. Brian Lanier, Commander, U.S. Army Institute of Surgical Research (USAISR).
- ends -
Enquiries
| Media David Snyder +1 978-749-1440 Smith+Nephew | |
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
FAQ
What is the significance of the partnership between Smith+Nephew and the USAISR?
What are the key areas of focus for Smith+Nephew under the Master CRADA?
How does the Master CRADA benefit both the Department of Defense and industry leaders?
Who is the President of Advanced Wound Management and Commercial Operations at Smith+Nephew?
Who is the Commander of the U.S. Army Institute of Surgical Research (USAISR)?
